Ipsen and Biomunex Pharmaceuticals announced an exclusive global licensing agreement for BMX-502. BMX-502 is a bispecific antibody that engages and activates a subset of...
Ipsen and Marengo Therapeutics Inc, a clinical-stage biotech company, announced the expansion of their ongoing oncology research partnership, to include TriSTAR, Marengo’s next-generation, precision...
